3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Bevacizumab
12
Paclitaxel
11
olaparib
10
Specimen Handling
10
Carboplatin
10
Magnetic Resonance Spectroscopy
9
liposomal doxorubicin
8
Biopsy
5
mirvetuximab soravtansine
4
Topotecan
4
Taxes
4
Immunoglobulin G
4
Gemcitabine
4
Disulfides
4
pembrolizumab
3
cediranib
3
Doxorubicin
3
sarilumab
2
niraparib
2
cemiplimab
2
Oxaliplatin
2
1-dodecylpyridoxal
2
tremelimumab
1
trastuzumab deruxtecan
1
tocilizumab
1
sotorasib
1
peposertib
1
pelcitoclax
1
palbociclib
1
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Histamine H2 Antagonists
×
30 days
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled